期刊
ONCOTARGETS AND THERAPY
卷 10, 期 -, 页码 21-30出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S90459
关键词
immunotherapy; non-small-cell lung cancer; nivolumab; pembrolizumab; ipilimumab; clinical trials; PD1; PDL1; CTLA4
资金
- Pierre Fabre
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD- 1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据